The risk of development of primary biliary cholangitis among  incidental antimitochondrial M2 antibody-positive patients

ergenç, ilkay; Gozaydinoglu, Busra; Keklikkiran, Caglayan; Yilmaz, Yusuf

doi:10.14744/hf.2023.2023.0016

The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients

İlkay ERGENÇ, (Marmara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, İstanbul, Türkiye)

Busra Gozaydinoglu, (Marmara Üniversitesi, Tıp Fakültesi, İstanbul, Türkiye)

Caglayan KEKLİKKİRAN, (Recep Tayyip Erdoğan Üniversitesi, Rize Eğitim ve Araştırma Hastanesi, Gastroenteroloji Bölümü, Rize, Türkiye)

Yusuf YILMAZ (Marmara Üniversitesi, Tıp Fakültesi, Gastroenteroloji Anabilim Dalı, İstanbul, Türkiye)

Hepatology forum

10 0

Yıl: 2023 Cilt: 4 Sayı: 2 Sayfa Aralığı: 69 - 73 Metin Dili: İngilizce DOI: 10.14744/hf.2023.2023.0016 İndeks Tarihi: 03-06-2023

The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients

Öz:

Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2. Materials and Methods: We retrospectively reviewed extractable nuclear antibody (ENA) panel test results to identify the incidental AMA-M2- positive patients. Patients who filled the diagnostic criteria for PBC were excluded. AMA-M2-positive patients were further evaluated by physical examination, liver biochemistry, liver ultrasonography, and transient elas tography (TE) and were also closely followed. Results: We included 48 (n=45, 93% female) individuals with a median age of 49 (range: 20–69) years. The median follow-up duration was 27 months (range: 9–42) after the detection of AMA-M2. Thirty-three (69%) patients had concomitant autoimmune/inflammatory disorders. Twenty-eight (58%) individuals showed seropositivity for ANA, and 21 had (43%) positive AMA. Fifteen (31%) patients developed typical PBC according to the international PBC diagnostic criteria during the follow-up, and five of them (18%) had significant fibrosis (≥8.2 kPA) by TE at the time of PBC diagnosis. Conclusion: Two-thirds of the incidental AMA-M2-positive patients devel oped typical features of PBC after a median 27-month follow-up. Our re sults suggest that AMA-M2 patients should be closely followed up to detect the late development of PBC

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. European Association for the Study of the Liver. Electronic address: easlof fice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67(1):145-172.
2. Bassendine MF, Jones DE, Yeaman SJ. Biochemistry and autoimmune re sponse to the 2-oxoacid dehydrogenase complexes in primary biliary cirrho sis. Semin Liver Dis 1997;17(1):49-60.
3. Shuai Z, Wang J, Badamagunta M, Choi J, Yang G, Zhang W, et al. The fin gerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology 2017;65(5):1670-1682.
4. Colapietro F, Lleo A, Generali E. Antimitochondrial antibodies: from bench to bedside. Clin Rev Allergy Immunol 2022;63(2):166-177.
5. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002;97(4):999-1002.
6. Chen CH, Lee CM, Chen CH, Hu TH, Wang JH, Hung CH, et al. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hep atitis C. Chang Gung Med J 2010;33(3):258-265.
7. Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC, Chang FY, Lee SD. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gas troenterol Hepatol. 1998 May;13(5):475-479.
8. Mitchison HC, Bassendine MF, Hendrick A, Bennett MK, Bird G, Watson AJ, et al. Positive antimitochondrial antibody but normal alkaline phos phatase: is this primary biliary cirrhosis? Hepatology 1986;6(6):1279- 1284.
9. Dahlqvist G, Gaouar F, Carrat F, Meurisse S, Chazouillères O, Poupon R, et al; French network of Immunology Laboratories. Large-scale characteriza tion study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology 2017;65(1):152-163.
10. Zandanell S, Strasser M, Feldman A, Tevini J, Strebinger G, Niederseer D, et al. Low rate of new-onset primary biliary cholangitis in a cohort of an ti-mitochondrial antibody-positive subjects over six years of follow-up. J Intern Med 2020;287(4):395-404.
11. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386(10003):1565-1575. Erratum in: Lancet 2015;386(10003):1536.
12. Bargou I, Mankaï A, Jamaa A, Ben Jazia I, Skandrani K, Sfar H, et al. Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay. Pathol Biol (Paris) 2008;56(1):10-14.
13. Poyatos E, Morandeira F, Climent J, Mas V, Castellote J, Bas J. Detection of anti-mitochondrial 2-oxoacid dehydrogenase complex subunit’s antibodies for the diagnosis of primary biliary cholangitis. Clin Immunol 2021:108749.
14. Leuschner U. Primary biliary cirrhosis--presentation and diagnosis. Clin Liver Dis 2003;7(4):741-758.
15. Liu HY, Wang LX, Liu YF. [Frequencies of autoantibodies specific for pri mary biliary cirrhosis in a general adult population group]. Zhonghua Gan Zang Bing Za Zhi. 2008 Dec;16(12):922-5. [Chinese]
16. Jiang XH, Zhong RQ, Fan XY, Hu Y, An F, Sun JW, et al. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroen terol 2003;9(9):2128-2131.
17. Guo Y, Wang C, Liu X, Liu J, Wang M, Gao Z, et al. [Evaluation of markers associated with primary biliary cirrhosis in a population of anti-mitochon drial antibody-M2-positive individuals]. Zhonghua Gan Zang Bing Za Zhi 2014;22(10):735-738. [Chinese]
18. Chen B, Wu X, Su C, Zhao L. Screening of anti-M2 mitochondrial antibody in elderly population. Chin J Gen Pract 2014;6:680-682.
19. Karakaya F, Oztekin S, Ozturk Y, Kalkan C, Ellik ZM. Elhan AH, et al. Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease. Hepatol Forum 2021;2(1):3-6.
20. Demir N, Efe C, Olmez S, Onur A, Yoshida EM. Anti-SLA and AMA-pos itive celiac disease: A report of two cases and evaluation of autoimmune liver serology. Hepatol Forum 2020;1(2):68-71.
21. Efe C, Wahlin S, Ozaslan E, Berlot AH, Purnak T, Muratori L, et al. Au toimmune hepatitis/primary biliary cirrhosis overlap syndrome and asso ciated extrahepatic autoimmune diseases. Eur J Gastroenterol Hepatol 2012;24(5):531-534.
22. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet 1996;348(9039):1399-1402.
23. Duan W, Chen S, Li S, Lv T, Li B, Wang X, et al. The future risk of pri mary biliary cholangitis (PBC) is low among patients with incidental an ti-mitochondrial antibodies but without baseline PBC. Hepatol Commun 2022;6(11):3112-3119.

APA	ergenç i, Gozaydinoglu B, Keklikkiran C, Yilmaz Y (2023). The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. , 69 - 73. 10.14744/hf.2023.2023.0016
Chicago	ergenç ilkay,Gozaydinoglu Busra,Keklikkiran Caglayan,Yilmaz Yusuf The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. (2023): 69 - 73. 10.14744/hf.2023.2023.0016
MLA	ergenç ilkay,Gozaydinoglu Busra,Keklikkiran Caglayan,Yilmaz Yusuf The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. , 2023, ss.69 - 73. 10.14744/hf.2023.2023.0016
AMA	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. . 2023; 69 - 73. 10.14744/hf.2023.2023.0016
Vancouver	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. . 2023; 69 - 73. 10.14744/hf.2023.2023.0016
IEEE	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y "The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients." , ss.69 - 73, 2023. 10.14744/hf.2023.2023.0016
ISNAD	ergenç, ilkay vd. "The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients". (2023), 69-73. https://doi.org/10.14744/hf.2023.2023.0016

APA	ergenç i, Gozaydinoglu B, Keklikkiran C, Yilmaz Y (2023). The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum, 4(2), 69 - 73. 10.14744/hf.2023.2023.0016
Chicago	ergenç ilkay,Gozaydinoglu Busra,Keklikkiran Caglayan,Yilmaz Yusuf The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum 4, no.2 (2023): 69 - 73. 10.14744/hf.2023.2023.0016
MLA	ergenç ilkay,Gozaydinoglu Busra,Keklikkiran Caglayan,Yilmaz Yusuf The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum, vol.4, no.2, 2023, ss.69 - 73. 10.14744/hf.2023.2023.0016
AMA	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum. 2023; 4(2): 69 - 73. 10.14744/hf.2023.2023.0016
Vancouver	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients. Hepatology forum. 2023; 4(2): 69 - 73. 10.14744/hf.2023.2023.0016
IEEE	ergenç i,Gozaydinoglu B,Keklikkiran C,Yilmaz Y "The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients." Hepatology forum, 4, ss.69 - 73, 2023. 10.14744/hf.2023.2023.0016
ISNAD	ergenç, ilkay vd. "The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients". Hepatology forum 4/2 (2023), 69-73. https://doi.org/10.14744/hf.2023.2023.0016